MedImmune/Wyeth FluMist
Executive Summary
MedImmune's intranasal flu vaccine FluMist receives recommendation from Advisory Committee on Immunization Practices Sept. 25 for use in healthy people ages 5 to 49 years of age. MedImmune has shipped 2.4 mil. doses to date; Wyeth's DTC ad campaign is underway (1"The Pink Sheet" Sept. 22, 2003, p. 16)...
You may also be interested in...
FluMist Reimbursement Is Ahead Of Plan; TV Ads Will Begin Sept. 29
The initial coverage decisions for the FluMist nasal flu vaccine indicate that MedImmune and Wyeth will be able to maintain the $46 per dose price of the vaccine
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.